San Carlos, Calif. -- Cellerant Therapeutics, a San Carlos-based biotechnology
firm developing products and services focused on the regulation of the
hematopoietic (blood-forming) system, said that it has raised $9 million to cap
its second round of funding at $25 million. Camelot Ventures, Amgen founder
George Rathmann and Eminent Venture Capital participated in the second
closing, after Novel Bioventures led the first closing. Cellerant said that the
capital will allow it to advance its program for the treatment of sickle cell
disease, as well as those for the treatment of autoimmune diseases and radiation-
and chemotherapy-induced neutropenia.
http://biz.yahoo.com/bw/050922/225076.html?.v=1
Sponsors
Listings
Notices
Recent Posts
- San Jose-Based Nanosolar Raises $70 Million in New Funding
- S.F.-Based Thayer Ventures to Invest in Hospitality Technology Startups
- Mountain View-Based Google Acquires Trust-Score Service KikScore
- OneSpin Solutions Lands Funding, Names New CEO
- Palo Alto-Based Diffbot Lands $2 Million in Funding from Tech Execs
- Opnet Technologies Acquires Redwood City-Based Clarus Systems
- Fremont-Based Redwood Systems Lands $11.75M in Third Round
- Redwood City-Based Shutterfly Acquires Photoccino
- Danaher to Acquire San Mateo-Based VSS Monitoring
- Founder Trip Hawkins to Depart as CEO of Digital Chocolate
Editor: Rich Scherr
For news tips and editorial issues,
contact editor Rich Scherr at
rich@techwiremedia.com
For advertising information, contract
Parul Nath at parul@techwiremedia.com
A Service of Tech Wire Media
Archives
- May 27, 2012 - June 2, 2012
- May 20, 2012 - May 26, 2012
- May 13, 2012 - May 19, 2012
- April 29, 2012 - May 5, 2012
- April 22, 2012 - April 28, 2012
- April 15, 2012 - April 21, 2012
- April 8, 2012 - April 14, 2012
- April 1, 2012 - April 7, 2012
- March 25, 2012 - March 31, 2012
- March 18, 2012 - March 24, 2012
